Company Profile: TheraVet is a Walloon vet biotech company targeting osteoarticular diseases in companion animals, and dogs in particular. Its business concept is to develop therapies for companion animals responding to the current market trends based on a robust safety and efficacy dossier. There are currently two different technologies in the company development pipeline:
- BIOCERA-VET: A line of synthetic injectable self-hardening calcium-phosphate bone void fillers with high porosity and a full range of micro, meso and macropore sizes.
BIOCERAVET is targeting the indications in Non-unions, bone defects, comminuted fractures and add-on to surgery.
It has an exclusive worldwide license for development/distribution 1 patent families granted CE marked/510k product (human).
- VISCO-VET: A versatile line of enhanced visco-antalgics with anti-inflammatory and pro-regenerative properties, also developed in a PRP-like (VV-PRP) version.
VISCO-VET is targeting the indications in Intra & extra-articular tendon/ligament injuries (TLI) and Osteoarthritis (OA).
It has a solid IP Position with 3 patent families and applications covering VISCO-VET technology